Palvella Therapeutics (PVLA) Liabilities and Shareholders Equity: 2013-2024
Historic Liabilities and Shareholders Equity for Palvella Therapeutics (PVLA) over the last 11 years, with Sep 2024 value amounting to $20.5 million.
- Palvella Therapeutics' Liabilities and Shareholders Equity fell 65.44% to $20.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $82.6 million, marking a year-over-year decrease of 74.55%. This contributed to the annual value of $7.5 million for FY2023, which is 92.10% down from last year.
- As of Q3 2024, Palvella Therapeutics' Liabilities and Shareholders Equity stood at $20.5 million, which was down 18.08% from $25.1 million recorded in Q2 2024.
- In the past 5 years, Palvella Therapeutics' Liabilities and Shareholders Equity registered a high of $164.2 million during Q3 2021, and its lowest value of $7.5 million during Q4 2023.
- For the 3-year period, Palvella Therapeutics' Liabilities and Shareholders Equity averaged around $68.9 million, with its median value being $82.3 million (2023).
- Per our database at Business Quant, Palvella Therapeutics' Liabilities and Shareholders Equity surged by 46.23% in 2021 and then plummeted by 92.10% in 2023.
- Over the past 5 years, Palvella Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $105.0 million in 2020, then spiked by 46.23% to $153.6 million in 2021, then crashed by 37.82% to $95.5 million in 2022, then slumped by 92.10% to $7.5 million in 2023, then slumped by 65.44% to $20.5 million in 2024.
- Its Liabilities and Shareholders Equity was $20.5 million in Q3 2024, compared to $25.1 million in Q2 2024 and $29.5 million in Q1 2024.